Pharmaceutical companies are manufacturers of original drugs. World ranking of pharmaceutical companies

As in any field, in the services market among pharmaceutical companies Russia has a rating the best manufacturers medications. There are more than 950 drug manufacturing companies in Russia. A third of the pharmacy market is occupied by companies that are located at the very top of the ranking of the best manufacturers. The value of drug sales determines the place of a pharmaceutical company in the ranking of the strongest.

Novartis

The drug manufacturing company Novartis is located in the most honorable place in the ranking. Novartis is the second largest in the world and produces such drugs as Linex, Amoxiclav, Otrivin. This company is Swiss.

Sanofi-Aventis

Bayer

Bayer took third place. Its main office is located in Germany. The corporation's branches operate in almost every country in the world. Bayer is actively involved in innovative drug development. The company's activities are dominated by natural sciences, Bayer collaborates with doctors, veterinarians and farmers to understand the most complex problems of our time.

Takeda

The pharmaceutical company Takeda took fourth place in the ranking of the strongest manufacturing companies in the pharmaceutical market. Takeda is a Japanese company and has opened its representative offices in more than seventy countries around the world. The global industry leader focuses on central nervous system diseases, metabolic diseases, oncology, cardiovascular diseases, and also produces vaccines.

Teva Pharmaceutical Industries Ltd

The headquarters of Teva Pharmaceutical Industries Ltd is located in Israel. This manufacturer is known for producing generic drugs. Teva products are distributed in 120 countries. 44 factories produce medicines, of which there are about 1,480 items. Teva Pharmaceutical Industries Ltd has been in the market for over a century. It was originally based in Jerusalem. In addition to generic drugs, the company develops innovative medicines in a variety of areas.

The corporations that are among the top five pharmaceutical manufacturing companies are the most active and successful. They are always busy developing new medicines, which suit the requirements of humanity. These companies never stand still. They are expanding, improving the quality of medicines, and are reliable suppliers of pharmaceutical products to the market.

The global pharmaceutical landscape is constantly changing - new companies are emerging, former outsiders are emerging at the forefront, and leaders are failing to cope with increased pressure. In this publication, we will analyze the successes and failures of the top 50 leading global companies based on the results of 2015 and try to understand what is the key to the success of leaders. Below are the top 50 pharmaceutical companies by global sales of prescription drugs according to the analytical company Evaluate Ltd, indicating the sales volume of top drugs and total investments in R&D at the end of 2015.

This ranking is the result of important changes in the global pharmaceutical market and business model transformations in the healthcare sector. At the same time, it is expected that the landscape of the pharmaceutical market will continue to change under the influence of both new players and innovative trends.

The total prescription drug sales of the companies in the top 50 amounted to more than $620 billion. USA, and total investments in R&D exceeded $110 billion. (table).

Source: data from the analytical company Evaluate Ltd

The ranking represents 18 pharmaceutical companies headquartered in the USA, 8 in Japan, 4 in Germany, 3 in Switzerland, 3 in Ireland, 2 in the UK, 2 in France and 1 each in Denmark, Israel, Canada, Australia, India, Spain, Belgium, Italy, South Korea and South Africa. It should be noted that the total number of European pharmaceutical companies is also 18. However, among the European pharmaceutical companies there are no enterprises from Central and Eastern European countries.

Although the companies represented in the top 50 global leaders by sales by value have remained remarkably stable over time, their relative positions on the list continue to change. This reflects the importance that the launch of a new drug and successful promotion existing drugs at each stage life cycle products currently play a key role in obtaining competitive advantage in sales. This helps explain why Pfizer returned to its position as the leader in prescription drug sales by value this year, displacing Novartis from the No. 1 spot. The key to Pfizer's success in this context was the increase in sales in the vaccine segment, which Novartis recently left, thanks in part to strong sales of the American company's pneumococcal vaccine Prevnar 13.

Further down the ranking, we find signs of a noticeable pause in the rise to the top of mid-market companies with innovative products and a fresh approach to their marketing that could make it into the top 10. However, so far only one of them has managed to reach this high bar - this feat was accomplished by Gilead Sciences, which jumped from 25th place to 9th the year before. This became possible thanks to the development of a drug for the treatment of hepatitis, which became a real breakthrough in this direction and provided a record high sales volume for the company. But having set this high bar, the company must now continue to meet expectations stock markets- it’s time for an encore, otherwise Gilead Sciences risks not maintaining its position in the top 10 pharmaceutical companies in terms of sales in monetary terms. In addition, the emergence of generic pharmaceutical companies in the top 10 is also not far off. Thus, Teva, which already has a huge product portfolio, recently acquired the generic business of Allergan. However, Teva's move into the top 10 could be hampered by price cuts, delays in some product launches and other regulatory issues.

In 2015, the ranking included 3 American companies"Meda", "Regeneron" and "Baxalta", as well as the Korean "CJ" and the Swiss "Nestle", displacing Baxter International (USA, 21st place), Stada Arzneimittel (Germany, 45th place) from the top 50 -th place), “Lundbeck” (Denmark, 49th place), “Kyowa Hakko Kirin” (Japan, 50th place). Also leaving the ranking was Actavis, which completed its acquisition of Allergan in early 2015 and changed its corporate name to Allergan. The transaction amount was $70.5 billion. in money and securities. The company's management expected that this combination could create one of the top 10 pharmaceutical companies by sales volume with expected revenue in 2015 of more than $23 billion. However, according to the results of sales of prescription drugs, Allergan failed to enter the top 10, while, however, improving its position in the ranking by 14 points compared to Allergan and by 7 compared to Actavis. , taking 12th position with sales of prescription drugs at the end of 2015 amounting to more than $18 billion.

Traditionally, leading Big Pharma players have focused on developing innovative, often first-in-class drugs that are destined to become blockbusters. Therefore, it is quite natural that pharmaceutical companies included in the top 10 invest heavily in R&D (Fig. 1). At the same time, many of them occupy leading positions in terms of investment in R&D not only within the healthcare sector, but also in on a global scale. Thus, according to PricewaterhouseCoopers, such pharmaceutical companies as Roche, Novartis, Johnson & Johnson, Pfizer, Merck & Co., Sanofi, GlaxoSmithKline and AstraZeneca are among the top 20 companies by volume of investments in R&D in 2015 among all industry representatives.

The largest Russian pharmaceutical companies earned from 15 billion rubles (PJSC Pharmstandard) to 182 billion rubles (JSC NPK Katren) in annual revenue at the end of 2015.

In the last two years, 2015 and 2016, the Russian pharmaceutical industry has shown significant growth - more than 20% in 2016, according to the Minister of Industry and Trade of the Russian Federation Denis Manturov.

At a briefing held at the Russian Ministry of Industry and Trade, Deputy Minister Sergei Tsyb said that the best evidence of the growth of the domestic pharmaceutical industry is that the American pharmaceutical giants are outraged: it is difficult for them to break into Russian market, as they are being replaced by large pharmaceutical companies in Russia. We analyzed and prepared the Top 7 largest Russian pharmaceutical holdings by revenue for 2015.

Pharmstandard

Legal address: Moscow

Registration date: 1996

Founders: Minin Alexander Nikolaevich, Kuznetsov Igor Gennadievich.

General manager: Kuznetsov Igor Gennadievich

• Authorized capital: 1,000,012.86 rub.
• Fixed assets: 153,955 thousand rubles
• Revenue: 21,191,811
• Accounts receivable: 2,667,522 thousand rubles
• Accounts payable: 6,961,274 thousand rubles.
• Net profit: 1,042,833 thousand rubles
• Net assets: 2,646,595 thousand rubles
• INN - 7731241639

http://www.euro-service.ru/

Sia International

Joint Stock Company "Sia International LTD" is engaged in the sale of medicines and medical products to pharmacies and medical institutions.

It has warehouse complexes in Moscow and more than 35 cities of Russia. Their total area is more than 200 thousand. square meters.

Legal address: Moscow city

Registration date: 1995

Founders: JSC "Rink", Rudinsky Igor Feliksovich.

General manager: Demkin Alexander Yurievich

• Authorized capital: 20,000,000 rubles
• Fixed assets: 5,624,687 thousand rubles.
• Revenue: 59,438,184 thousand rubles
• Accounts receivable: 13,597,841 thousand rubles.
• Accounts payable: 20,209,002 thousand rubles.
• Net profit: -3,111,114 thousand rubles
• Net assets: 2,908,224 thousand rubles
• TIN - 7714030099

Sources: official website: http://siamed.ru/, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

R-Pharm

Joint Stock Company "R-Pharm" specializes in high-tech medicines. The company is currently working towards large-scale investment projects.

It is creating a production base as part of the state strategy for the development of the Russian pharmaceutical industry until 2020.

Legal address: Moscow

Registration date: 2001

Founders: Repik Alexey Evgenievich

General manager: Ignatiev Vasily Gennadievich

• Authorized capital: RUB 28,400.
• Fixed assets: 2,119,636 thousand rubles
• Revenue: 62,204,014 thousand rubles
• Accounts receivable: 13,435,674 thousand rubles.
• Accounts payable: 30,682,362 thousand rubles
• Net profit: 8,608,010 thousand rubles.
• Net assets: 24,205,818 thousand rubles
• INN - 7726311464

Sources of information: official website: http://r-pharm.com, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Growth

Closed joint stock company"Growth." In total, the Rosta pharmaceutical group includes 4 companies: Rosta (engaged in the distribution of medicines), Rosta Marketing (trade marketing), Raduga Production (a plant for the production of solid medicines), United Pharmacy Chain, which includes the companies “Rainbow”, “First Aid”, “Ladushka”.

Legal address: Moscow region, city of Podolsk

Registration date: 2002

Founders: Joint Stock PJSC company“Tampo”, Mirilashvili Mikhail Mikhailovich, Panikashvili David Isaakovich, Tseytlin Oleg Yakovlevich, Strepetov Vadim Valentinovich, Shepel Boris Albertovich, Semenyuk Alexander Vasilievich, Konev Oleg Yurievich.

President: Panikashvili David Isaakovich

• Authorized capital: 1,000,000 rubles
• Fixed assets: 621,356 thousand rubles
• Revenue:63,384,563 thousand rubles
• Accounts receivable: 18,293,282 thousand rubles.
• Accounts payable: 35,244,901 thousand rubles
• Net profit: 415,314 thousand rubles
• Net assets: 1,755,002 thousand rubles.
• INN - 7726320638

Sources: official website: http://www.rostagroup.ru/, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Protek

Closed joint stock company "Implementation Center "Protek". The Protek group of companies is engaged in the production, distribution and retail sales through pharmacy chains of drugs.

The holding's production and technological capacities comply with GMP standards.

Legal address: Moscow

Registration date: 1994

Founders: JSC "Protek"

General manager: Pogrebinsky Dmitry Borisovich

• Authorized capital: 40,000,000 rubles
• Fixed assets: 1,082,865 thousand rubles.
• Revenue: 166,578,310 thousand rubles
• Accounts receivable: 32,742,113 thousand rubles.
• Accounts payable: 69,059,867 thousand rubles
• Net profit: RUB 5,419,719.
• Net assets: 8,094,159 rubles
• INN - 7724053916

Sources of information: official website of the company: http://www.protek-group.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Quatrain

The geography of Katren's work covers 85 constituent entities of the Russian Federation and delivers more than 18 thousand types of pharmaceutical products.

Legal address: Novosibirsk city

Registration date: 1993

Founders: Konobeev Leonid Valentinovich, Spiridonov Vladimir Nikolaevich

General manager: Konobeev Leonid Valentinovich

• Authorized capital: 1 billion 500 million rubles
• Fixed assets: 6,752,880 thousand rubles
• Revenue: 182,301,551 thousand rubles
• Accounts receivable: 30,155,368 thousand rubles.
• Accounts payable: 65,656,588 thousand rubles
• Net profit: 5,790,742 thousand rubles
• Net assets: 11,103,940 thousand rubles.
• INN - 5408130693

Sources: official website: http://katren.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

On December 19 in Moscow, the National Pharmaceutical Rating awarded the best manufacturers of medicines and medicinal cosmetics, as well as the most successful brands.

Selection of nominees built on objective indicators – sales volumes of pharmaceutical products. The rating is based on independent research and analytics from DSM Group.

Results of the “National Pharmaceutical Rating - 2017”:

• The company won in the Rx-manufacturer category, with Pfizer in second place and Pfizer in third.
• The company topped the OTC Manufacturer nomination "OTCPharm", followed by Bayer, and Johnson & Johnson closes the top three.
• In the “OTC-drug” category the first place is taken by "Kagocel", on the second - "Nurofen", on the third - "Ingavirin".
• The brand won the Rx-drug category "Prevenar 13", in second place is Revlimid, in third place is Kaletra.
• In the nomination “Rx-drug on the pharmacy market” the first place is taken by "Concor", on the second – “Actovegin”, on the third – “Xarelto”.
• In the nomination “Dietary Supplement Manufacturer”, the first place, as in the previous year, is taken by the company "Evalar", in second place is PharmaMed, and Solgar Vitamin and Herb closes the top three.
• First place in the category “Brand Dietary Supplements” Solgar, in second place is the brand “Doppelgerts”, in third place is “Vitamishki”.
• In the category "Cosmetics Manufacturer" in first place - L'Oréal, followed by the Zeldis-Pharma company, and Pierre Fabre closes the top three.
• In the “Cosmetics Brand” category – first place – Librederm, in second place is La Roche Posay, in third place is Vichy.
• In the “Toothpaste Brand” category, the leaders were distributed as follows: in first place R.O.C.S., on the second Lacalut, on the third Splat.
• Nomination “Wound care products and first aid. Manufacturer" was headed by the company Paul Hartmann, in second place is Johnson & Johnson, in third place is Veropharm.

“The purpose of the National Pharmaceutical Rating is to evaluate the results of work and identify leaders in terms of sales volume in Russia over the past year, recognize the best in the industry and deservedly reward those who provide the country with quality medicines and value the social component of their activities. This year’s ceremony is distinguished by an important charitable mission: along with summing up the results of the rating, we collected gifts for two orphanages and for the House of Stage Veterans named after. A. Yablochkina. Next week we will organize the transfer of all the gifts, and this will be another small but pleasant occasion in creating a New Year’s mood for everyone,” says general manager DSM Group Sergey Shulyak.

The awards ceremony for the nominees of the National Pharmaceutical Rating brought together more than 300 participants and guests, leading show business artists, the media, as well as top managers of pharmaceutical companies and industry associations. The award ceremony was celebrated in the Miх Afreparty hall with the energy of a real rock party, with drive and in an unusual way official events format.

Over the past 12 months pharmaceutical market demonstrates strong growth, which means that the income of drug manufacturers is growing steadily. Pharmaceuticals are traditionally considered one of the most profitable sectors of the economy.

However, entering this market is not at all easy, because large manufacturers invest billions of dollars in drug development, patenting and sales. Today we present rating of the largest pharmaceutical companies, which presents the world's main players in the medicinal industry.

The company was founded in 1863 in Germany. Bayer produces pharmaceuticals for humans and animals, food additives, and agrochemical fertilizers.

9.Merck & Co

The headquarters of this pharmaceutical company is located in New Jersey, USA. Merck & Co. was founded in 1891 as a subsidiary of the German company Merck KGaA. During the war, the division was confiscated by the American government and turned into an independent company.

8. Abbott Laboratories

The American pharmaceutical company was founded in 1888. And in 2010, Abbott Laboratories' turnover exceeded $35 billion. The company employs more than 91 thousand people.

The Swedish-British company was founded in 1999 by merging the Swedish Astra AB with the British Zeneca. AstraZeneca's turnover is about $25 billion. Today the pharmaceutical company employs more than 50 thousand people.

The French pharmaceutical company produces drugs for various diseases, vaccines, oncology drugs, etc. At the same time, Sanofi is an employer of 112 thousand people.

The Swiss company was founded in 1996. Novartis' subsidiary brands include contact lens manufacturers Alcon and Ciba Vision, as well as pharmaceutical company Sandoz.

The British pharmaceutical company has offices in 114 countries. GSK operates 24 research and development laboratories. The company's employees are 99 thousand people.

The Swiss holding is active in the market of innovative drugs. F. Hoffmann-La Roche owns three subsidiaries operating in the field of biotechnology. The holding is an employer of 85 thousand people.

The American company was founded in 1849 by two cousins, immigrants from Germany. The company's turnover today exceeds $51 billion. Pfizer employees are 78 thousand people.

The world's largest pharmaceutical company produces in addition to medicines and medical supplies household chemicals, contact lenses, cosmetics and medical equipment. The company's turnover is 471 billion per year. Johnson & Johnson employs 128 thousand people.